| ID | 1111 |
| Name of the vaccine | PBT |
| Microbe | Bacteria |
| Disease name | Botulism |
| Name of bacteria | Clostridium botulinum |
| Type of vaccine | Toxoid |
| Nucleic acid content | DNA |
| Age | NA |
| Description of the vaccine | Pentavalent botulinum toxoid against serotypes A through E and was distributed for human use until November 1981. |
| Name of the manufacturer | Michigan Department of Public Health (MDPH) |
| Name of the manufacturing country | NA |
| Year of manufacture | 1970 to 1981 |
| Clinical Phase status | Clinical - Discontinued |
| Bacterial strain | Gram-positive anaerobic bacterium. |
| Efficacy | NA |
| Vaccine formulation | NA |
| Dosage | 0.5-ml dose in 0, 2, 12, 26, and 52 weeks, with annual boosts. |
| Mechanism of action | Prevent the binding of the toxin to an appropriate receptor and promote clearance and degradation by phagocytes. |
| Route of administration | Subcutaneous |
| Indications | Used for at-risk workers and for use with military personnel at-risk during deployment. |
| Export | NA |
| Approval | Investigational New Drug (IND 161) held by the CDC and the U.S. Army Office of Surgeon General (IND 3723) |
| Adjuvant | Aluminium phosphate |
| Repurposing | NA |
| Side effects of vaccine | NA |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | 19837283 |
| Clinical trial number | NA |
| Reference | NA |
| Other name | NA |
| Additional Links | NA
|